Oncology Clinical Research

Oncology expertise you can trust

Oncology trials are complex—scientifically, operationally, and from a regulatory perspective. Our teams have both deep knowledge and hands‑on experience, supporting oncology clinical studies across multiple indications and development phases, often in multinational and multi‑site settings.

We support oncology programs with:

Clinical study design and feasibility
Clinical operations and monitoring
Regulatory strategy and submissions in the EU
Quality assurance and compliance support

Our combined clinical research and regulatory capabilities help to reduce trial risks and improve coordination, to keep oncology programs moving forward efficiently.

Who we work with

We partner with:

Biotech and pharmaceutical companies
Medical device and IVD developers
Academic and research organizations

Our teams support oncology programs from early development through clinical execution—always with a focus on quality, compliance, and patient safety. We have oncology trial experience across a broad range of indications, including:

Solid tumors: breast, lung, pancreatic, renal, colorectal, ovarian, and glioblastoma (GBM).
Hematologic malignancies: lymphomas, leukemias, and multiple myeloma.

Whether you need help with designing or expanding your clinical study, developing your regulatory strategy, or full-service support, contact us to explore how we can advance your oncology program.

Aurevia

Who we are

European CRO supporting US-based companies expanding clinical development into Europe

Aurevia is a mid-sized, full-service European Contract Research Organization (CRO) and regulatory partner with deep expertise in clinical research, quality assurance and regulatory affairs. We support companies in the development and execution of clinical research across Europe and beyond.

Our teams have extensive experience helping innovative pharma, biotech and medtech companies, as well as academic researchers, across the entire product lifecycle—from early development to post market phases.

What makes us different is our integrated approach. By combining clinical operations, regulatory expertise, and geographic reach in one partner, we help sponsors navigate complex European regulatory requirements and streamline trial execution to keep trials moving forward.

Why choose Aurevia?

Agile, mid‑sized CRO model: Our size allows us to be flexible, responsive, and hands-on, delivering tailored solutions rather than one-size-fits-all processes.
Local presence with broad European reach: With teams in Sweden, Germany, Poland, and Finland, and a strong European network, we support oncology trials across multiple countries and sites.
Integrated clinical research and regulatory services: Unlike CROs solely focused on trial execution, we combine clinical operations with regulatory strategy and submissions.
Strong European regulatory specialization: We have deep knowledge of EU regulatory frameworks, helping sponsors align European requirements with global development strategies.

A culture of collaboration

At Aurevia, our teams have a strong connection with each other, as well as with our customers and study sites. This close collaboration is valued by our customers and is the key to the project’s success.

Ulrika Heldestad

CRO BD & Sales Director at Aurevia

Excellence for customers

Our customer-centric approach means that our client’s needs guide our focus to create impactful results.

Reliability you can trust

We prioritize transparency, dependability, and delivering high-quality results.

Assured solutions

We deliver agile, tailored solutions through deep expertise and a commitment to excellence.

Your partner for oncology clinical trials

Oncology expertise you can trust

Who we work with

Who we are

European CRO supporting US-based companies expanding clinical development into Europe

Why choose Aurevia?

Let's discuss your needs

Together, we build trust in tomorrow's healthcare

Sitemap

Areas of expertise